| New from NCI |
| For Some Women with Breast Cancer, Cost Affects Choices about Surgery |
 |
|
Researchers surveyed nearly 600 breast cancer survivors and found that the cost of care factored into their decisions about what type of surgery to get. Many women also reported never discussing costs with their physicians. |
| Diet Change Improves Responses to Cancer Treatments |
 |
|
New research results suggest that attacking a tumor’s nutritional needs might improve the effects of chemotherapy and radiation. Read about the studies, in mice and in small numbers of people, that tested this concept. |
NCI’s Annual Plan & Budget Proposal Released
Each year, NCI prepares a plan for advancing cancer research and the funding required to make the most rapid progress against cancer. NCI Acting Director Douglas R. Lowy, M.D., announced this year’s plan—including the three emerging areas of research opportunity—in a recent Cancer Currents blog post. |
NCI-MATCH Precision Medicine Trial
The ongoing NCI-MATCH trial has two new arms now accepting patients. Learn about the types of cancer treated on this study and how people can enroll. |
Immunotherapy Approved for Cancer of the Esophagus
Pembrolizumab (Keytruda) has been approved by the Food and Drug Administration (FDA) to treat people with advanced cancer of the esophagus that has certain levels of the protein PD-L1. Read about the studies that led to this approval.
|
| PDQ Cancer Information Summary Updates |
Childhood Brain Stem Glioma Treatment
We’ve revised our PDQ summary on treatment for childhood brain stem glioma. Updates were made to the descriptions of the types of brain stem glioma, signs and symptoms of the disease, factors that affect prognosis, and treatment options for the disease. |
Lip and Oral Cavity Cancer Treatment
We’ve revised our PDQ summary on treatment for lip and oral cavity cancer with updated descriptions of the stages of this disease. |
| Drug Information Updates |
New Approval for Myelofibrosis
We've added a new drug information summary for fedratinib hydrochloride (Inrebic), which was recently approved by FDA to treat certain people with a rare bone marrow disease called myelofibrosis. |
